This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HELLMAN, L. Articles by FUKUSHIMA, D. K. Search for Related Content PubMed PubMed Citation Articles by HELLMAN, L. Articles by FUKUSHIMA, D. K.

The Effect of Medroxyprogesterone Acetate on the Pituitary-Adrenal Axis

Department of Oncology and Institute for Steroid Research, Montefiore Hospital and Medical Center Bronx, New York 10467

Twelve cancer patients and one patient with diabetes mellitus were treated with medroxyprogesterone acetate (MPA) by intramuscular injection in a total weekly dose of 400, 700, or 1200 mg. The treatment reduced the plasma cortisol concentration by 76% in the AM hours (21 5.0 µg/dl) and by 75% in the PM hours (12.8 3.2 µg/dl). Cortisol production rate decreased by 67% (19 6.2 mg/24 hrs). The 24 hour profile of plasma cortisol concentration measured in 3 patients showed zero secretion over this period. Low plasma ACTH values prevailed during treatment, and a blunted response to maximal ACTH stimulation was found. No evidence of adrenal insufficiency was observed in any patient, even though in some patients the plasma cortisol concentration remained at zero for many weeks. MPA has cortisol-like effects and the suppression of adrenal function is probably mediated by a negative feedback action on the hypothalamus or pituitary.

Received September 2, 1975.

This article has been cited by other articles:

				B. J. MONTELLA, J. A. NUNLEY, and J. R. URBANIAK Osteonecrosis of the Femoral Head Associated with Pregnancy. A Preliminary Report J. Bone Joint Surg. Am., June 1, 1999; 81(6): 790 - 8. [Abstract] [Full Text]

				I. Schiff, D. Tulchinsky, D. Cramer, and K. J. Ryan Oral Medroxyprogesterone in the Treatment of Postmenopausal Symptoms JAMA, September 26, 1980; 244(13): 1443 - 1445. [Abstract] [PDF]